Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial.

van der Ree MH, de Vree JM, Stelma F, Willemse S, van der Valk M, Rietdijk S, Molenkamp R, Schinkel J, van Nuenen AC, Beuers U, Hadi S, Harbers M, van der Veer E, Liu K, Grundy J, Patick AK, Pavlicek A, Blem J, Huang M, Grint P, Neben S, Gibson NW, Kootstra NA, Reesink HW.

Lancet. 2017 Feb 18;389(10070):709-717. doi: 10.1016/S0140-6736(16)31715-9. Epub 2017 Jan 11.

PMID:
28087069
2.

Engineered microRNA therapeutics.

Gibson NW.

J R Coll Physicians Edinb. 2014;44(3):196-200. doi: 10.4997/JRCPE.2014.302. Review.

PMID:
25318394
3.

NOTCH1 signaling promotes human T-cell acute lymphoblastic leukemia initiating cell regeneration in supportive niches.

Ma W, Gutierrez A, Goff DJ, Geron I, Sadarangani A, Jamieson CA, Court AC, Shih AY, Jiang Q, Wu CC, Li K, Smith KM, Crews LA, Gibson NW, Deichaite I, Morris SR, Wei P, Carson DA, Look AT, Jamieson CH.

PLoS One. 2012;7(6):e39725. doi: 10.1371/journal.pone.0039725. Epub 2012 Jun 29.

4.

Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer.

Wang K, Kan J, Yuen ST, Shi ST, Chu KM, Law S, Chan TL, Kan Z, Chan AS, Tsui WY, Lee SP, Ho SL, Chan AK, Cheng GH, Roberts PC, Rejto PA, Gibson NW, Pocalyko DJ, Mao M, Xu J, Leung SY.

Nat Genet. 2011 Oct 30;43(12):1219-23. doi: 10.1038/ng.982.

PMID:
22037554
5.

Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin.

Bhagwat SV, Gokhale PC, Crew AP, Cooke A, Yao Y, Mantis C, Kahler J, Workman J, Bittner M, Dudkin L, Epstein DM, Gibson NW, Wild R, Arnold LD, Houghton PJ, Pachter JA.

Mol Cancer Ther. 2011 Aug;10(8):1394-406. doi: 10.1158/1535-7163.MCT-10-1099. Epub 2011 Jun 14.

6.

Imidazo[1,5-a]pyrazines: orally efficacious inhibitors of mTORC1 and mTORC2.

Crew AP, Bhagwat SV, Dong H, Bittner MA, Chan A, Chen X, Coate H, Cooke A, Gokhale PC, Honda A, Jin M, Kahler J, Mantis C, Mulvihill MJ, Tavares-Greco PA, Volk B, Wang J, Werner DS, Arnold LD, Pachter JA, Wild R, Gibson NW.

Bioorg Med Chem Lett. 2011 Apr 1;21(7):2092-7. doi: 10.1016/j.bmcl.2011.01.139. Epub 2011 Feb 3.

PMID:
21353551
7.

Complexity in common diseases: big biology for all.

Lamb JR, Gibson NW.

Sci Transl Med. 2010 Mar 31;2(25):25cm11. doi: 10.1126/scitranslmed.3000882.

PMID:
20424010
8.

Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor.

Mulvihill MJ, Cooke A, Rosenfeld-Franklin M, Buck E, Foreman K, Landfair D, O'Connor M, Pirritt C, Sun Y, Yao Y, Arnold LD, Gibson NW, Ji QS.

Future Med Chem. 2009 Sep;1(6):1153-71. doi: 10.4155/fmc.09.89.

9.

Knockdown of Ron kinase inhibits mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma.

Wang J, Rajput A, Kan JL, Rose R, Liu XQ, Kuropatwinski K, Hauser J, Beko A, Dominquez I, Sharratt EA, Brattain L, Levea C, Sun FL, Keane DM, Gibson NW, Brattain MG.

J Biol Chem. 2009 Apr 17;284(16):10912-22. doi: 10.1074/jbc.M809551200. Epub 2009 Feb 18.

10.

Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.

Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Thomson S, Mulvihill M, Barr S, Brown E, O'Connor M, Yao Y, Pachter J, Miglarese M, Epstein D, Iwata KK, Haley JD, Gibson NW, Ji QS.

Cancer Res. 2008 Oct 15;68(20):8322-32. doi: 10.1158/0008-5472.CAN-07-6720.

11.

Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions.

Barr S, Thomson S, Buck E, Russo S, Petti F, Sujka-Kwok I, Eyzaguirre A, Rosenfeld-Franklin M, Gibson NW, Miglarese M, Epstein D, Iwata KK, Haley JD.

Clin Exp Metastasis. 2008;25(6):685-93. doi: 10.1007/s10585-007-9121-7. Epub 2008 Jan 31. Review.

12.

Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.

Mulvihill MJ, Ji QS, Coate HR, Cooke A, Dong H, Feng L, Foreman K, Rosenfeld-Franklin M, Honda A, Mak G, Mulvihill KM, Nigro AI, O'Connor M, Pirrit C, Steinig AG, Siu K, Stolz KM, Sun Y, Tavares PA, Yao Y, Gibson NW.

Bioorg Med Chem. 2008 Feb 1;16(3):1359-75. Epub 2007 Oct 23.

PMID:
17983756
13.

A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo.

Ji QS, Mulvihill MJ, Rosenfeld-Franklin M, Cooke A, Feng L, Mak G, O'Connor M, Yao Y, Pirritt C, Buck E, Eyzaguirre A, Arnold LD, Gibson NW, Pachter JA.

Mol Cancer Ther. 2007 Aug;6(8):2158-67. Epub 2007 Aug 1.

14.

Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis.

Wang J, Kuropatwinski K, Hauser J, Rossi MR, Zhou Y, Conway A, Kan JL, Gibson NW, Willson JK, Cowell JK, Brattain MG.

Mol Cancer Ther. 2007 Mar;6(3):1143-50.

15.

Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition.

Buck E, Eyzaguirre A, Barr S, Thompson S, Sennello R, Young D, Iwata KK, Gibson NW, Cagnoni P, Haley JD.

Mol Cancer Ther. 2007 Feb;6(2):532-41.

16.

Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.

Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD, Iwata KK, Gibson NW, Griffin G.

Mol Cancer Ther. 2006 Nov;5(11):2676-84.

18.

3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.

Mulvihill MJ, Kan JL, Cooke A, Bhagwat S, Beck P, Bittner M, Cesario C, Keane D, Lazarescu V, Nigro A, Nillson C, Panicker B, Smith V, Srebernak M, Sun FL, O'Connor M, Russo S, Fischetti G, Vrkljan M, Winski S, Castelhano AL, Emerson D, Gibson NW.

Bioorg Med Chem Lett. 2006 May 15;16(10):2729-33. Epub 2006 Feb 28.

PMID:
16504501
19.

OSI-930: a novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models.

Garton AJ, Crew AP, Franklin M, Cooke AR, Wynne GM, Castaldo L, Kahler J, Winski SL, Franks A, Brown EN, Bittner MA, Keily JF, Briner P, Hidden C, Srebernak MC, Pirrit C, O'Connor M, Chan A, Vulevic B, Henninger D, Hart K, Sennello R, Li AH, Zhang T, Richardson F, Emerson DL, Castelhano AL, Arnold LD, Gibson NW.

Cancer Res. 2006 Jan 15;66(2):1015-24.

20.

Regulation of fibroblast growth factor 2 expression in melanoma cells by the c-MYB proto-oncoprotein.

Miglarese MR, Halaban R, Gibson NW.

Cell Growth Differ. 1997 Nov;8(11):1199-210.

21.

Delivery of tumor suppressor genes to reverse the malignant phenotype.

Kennedy SP, Gibson NW.

Adv Drug Deliv Rev. 1997 Jul 7;26(2-3):119-133.

PMID:
10837538
22.

Preface.

Gibson NW.

Adv Drug Deliv Rev. 1997 Jul 7;26(2-3):69-70. No abstract available.

PMID:
10837534
23.

Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase).

Traver RD, Siegel D, Beall HD, Phillips RM, Gibson NW, Franklin WA, Ross D.

Br J Cancer. 1997;75(1):69-75.

24.

Role of NAD(P)H:quinone oxidoreductase (DT-diaphorase) in cytotoxicity and induction of DNA damage by streptonigrin.

Beall HD, Liu Y, Siegel D, Bolton EM, Gibson NW, Ross D.

Biochem Pharmacol. 1996 Mar 8;51(5):645-52.

PMID:
8615901
25.

Reactive oxygen species and DNA damage in 2-bromo-(glutathion-S-yl) hydroquinone-mediated cytotoxicity.

Mertens JJ, Gibson NW, Lau SS, Monks TJ.

Arch Biochem Biophys. 1995 Jun 20;320(1):51-8.

PMID:
7793984
26.
27.

Metabolism of bioreductive antitumor compounds by purified rat and human DT-diaphorases.

Beall HD, Mulcahy RT, Siegel D, Traver RD, Gibson NW, Ross D.

Cancer Res. 1994 Jun 15;54(12):3196-201.

28.
30.

Mitomycin C.

Gibson NW, Phillips RM, Ross D.

Cancer Chemother Biol Response Modif. 1994;15:51-7. Review. No abstract available.

PMID:
7779596
31.

Bioactivation of quinones by DT-diaphorase, molecular, biochemical, and chemical studies.

Ross D, Beall H, Traver RD, Siegel D, Phillips RM, Gibson NW.

Oncol Res. 1994;6(10-11):493-500. Review.

PMID:
7620217
32.

pH-dependent inactivation of DT-diaphorase by mitomycin C and porfiromycin.

Siegel D, Beall H, Kasai M, Arai H, Gibson NW, Ross D.

Mol Pharmacol. 1993 Dec;44(6):1128-34.

PMID:
8264549
35.

Sequence-selective alkylation and cross-linking induced by mitomycin C upon activation by DT-diaphorase.

Prakash AS, Beall H, Ross D, Gibson NW.

Biochemistry. 1993 Jun 1;32(21):5518-25.

PMID:
8504072
36.

DT-diaphorase in activation and detoxification of quinones. Bioreductive activation of mitomycin C.

Ross D, Siegel D, Beall H, Prakash AS, Mulcahy RT, Gibson NW.

Cancer Metastasis Rev. 1993 Jun;12(2):83-101. Review.

PMID:
8375023
37.

Two structurally related diaziridinylbenzoquinones preferentially cross-link DNA at different sites upon reduction with DT-diaphorase.

Berardini MD, Souhami RL, Lee CS, Gibson NW, Butler J, Hartley JA.

Biochemistry. 1993 Apr 6;32(13):3306-12.

PMID:
8461296
38.

The history of DNA reactive antitumour agents: is newer better?

Gibson NW.

J Pharm Pharmacol. 1993 Apr;45 Suppl 1:331-42. Review. No abstract available.

PMID:
8098740
39.
40.

Mitomycin C.

Gibson NW, Ross D.

Cancer Chemother Biol Response Modif. 1993;14:45-54. Review.

PMID:
8312113
41.

Bioreductive activation of mitomycin C by DT-diaphorase.

Siegel D, Beall H, Senekowitsch C, Kasai M, Arai H, Gibson NW, Ross D.

Biochemistry. 1992 Sep 1;31(34):7879-85.

PMID:
1510975
42.

Relationship between DT-diaphorase-mediated metabolism of a series of aziridinylbenzoquinones and DNA damage and cytotoxicity.

Gibson NW, Hartley JA, Butler J, Siegel D, Ross D.

Mol Pharmacol. 1992 Sep;42(3):531-6.

PMID:
1406604
43.

Alteration in DNA cross-linking and sequence selectivity of a series of aziridinylbenzoquinones after enzymatic reduction by DT-diaphorase.

Lee CS, Hartley JA, Berardini MD, Butler J, Siegel D, Ross D, Gibson NW.

Biochemistry. 1992 Mar 24;31(11):3019-25.

PMID:
1372518
44.

Effect of methylated forms of selenium on cell viability and the induction of DNA strand breakage.

Wilson AC, Thompson HJ, Schedin PJ, Gibson NW, Ganther HE.

Biochem Pharmacol. 1992 Mar 3;43(5):1137-41.

PMID:
1554385
45.
46.

NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity.

Traver RD, Horikoshi T, Danenberg KD, Stadlbauer TH, Danenberg PV, Ross D, Gibson NW.

Cancer Res. 1992 Feb 15;52(4):797-802.

47.

Mitomycin C.

Gibson NW, Siegel D, Ross D.

Cancer Chemother Biol Response Modif. 1992;13:59-68. Review. No abstract available.

PMID:
1389922
48.

DNA cross-linking and sequence selectivity of aziridinylbenzoquinones: a unique reaction at 5'-GC-3' sequences with 2,5-diaziridinyl-1,4-benzoquinone upon reduction.

Hartley JA, Berardini M, Ponti M, Gibson NW, Thompson AS, Thurston DE, Hoey BM, Butler J.

Biochemistry. 1991 Dec 17;30(50):11719-24.

PMID:
1751490
50.

Supplemental Content

Loading ...
Support Center